• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May-October 2021) in

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2023 Jan 18;10(1):ofad023.
doi: 10.1093/ofid/ofad023. eCollection 2023 Jan.
High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May-October 2021) in Matadi, Democratic Republic of the Congo


Yannick Munyeku-Bazitama[SUP] 1 2 3 [/SUP], Patient Okitale-Talunda[SUP] 3 [/SUP], Patrick Mpingabo-Ilunga[SUP] 3 [/SUP], Marc K Yambayamba[SUP] 4 [/SUP], Paul M Tshiminyi[SUP] 1 [/SUP], Aimé Umba-Phuati[SUP] 5 [/SUP], Jacques Kimfuta[SUP] 5 [/SUP], Ferdinand A Phukuta[SUP] 5 [/SUP], Goethe Makindu[SUP] 5 [/SUP], Raymond Mufwaya-Nsene[SUP] 6 [/SUP], Ryoko Asari[SUP] 6 [/SUP], Saeda Makimoto[SUP] 6 [/SUP], Lionel K Baketana[SUP] 1 [/SUP], Steve Ahuka-Mundeke[SUP] 1 3 [/SUP], Mitsuo Isono[SUP] 6 [/SUP], Justus Nsio-Mbeta[SUP] 7 [/SUP], Sheila Makiala-Mandanda[SUP] 1 3 [/SUP], Jean-Jacques Muyembe-Tamfum[SUP] 1 3 [/SUP]



Affiliations

Abstract

Background: By the end of the third wave of the coronavirus disease 2019 (COVID-19) epidemic (May-October 2021), only 3130 of the 57 268 confirmed cases of coronavirus disease 2019 (COVID-19) in the Democratic Republic of the Congo (DRC) were reported in Kongo Central. This province, and especially its capital city, Matadi, has essential trade and exchanges with Kinshasa, the epicenter of the COVID-19 epidemic in DRC. Kinshasa accounted for 60.0% of all cases during the same period. The true burden of COVID-19 in Matadi is likely underestimated. In this study, we aimed to determine the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence and associated risk factors after the third wave in Matadi.
Methods: We conducted a population-based cross-sectional study in October 2021. Consenting participants were interviewed and tested using an enzyme-linked immunosorbent assay commercial kit. We applied univariable and multivariable analysis to evaluate factors associated with seropositivity and adjusted the seroprevalence for the test kit performance.
Results: We included 2210 participants from 489 households. Female participants represented 59.1%. The median age was 27 years (interquartile range, 16-45 years). The crude SARS-CoV-2 seroprevalence was 82.3%. Age was identified as the main risk factor as younger age decreased the seropositivity odds. Accounting for clustering at the household level increased the seroprevalence to 83.2%. The seroprevalence increased further to 88.1% (95% confidence interval, 86.2%-90.1%) after correcting for the laboratory test kit performance.
Conclusions: The SARS-CoV-2 seroprevalence was very high, contrasting with reported cases. Evidence generated from this population-based survey remains relevant in guiding the local COVID-19 response, especially vaccination strategies.

Keywords: Matadi; SARS-CoV-2; antibodies; seroprevalence; third wave.
 
Back
Top Bottom